ABT Earnings Prediction
The chart below shows how ABT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABT sees a -0.94% change in stock price 10 days leading up to the earnings, and a +1.56% change 10 days following the report. On the earnings day itself, the stock moves by +0.31%. This data can give you a slight idea of what to expect for the next quarter's release.
ABT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.63B
4.85%
2.49%
Gross Margin
51.82%
3.95%
0.90%
Operating Margin
17.84%
6.44%
6.76%
Net Margin
15.48%
9.32%
23.35%
EPS
0.94
14.63%
27.03%
No Data Available
ABT Earnings Analysis
Abbott Laboratories Corporation (ABT.N) Earnings Conference Call
Positive
Strong Organic Sales Performance: Organic sales growth exceeded 8%, excluding COVID testing sales, with adjusted earnings per share reported at $1.21.
Nutrition Sales Growth: Nutrition sales increased by 3.5%, driven by a 12% growth in U.S. pediatric nutrition and 11.5% growth in U.S. adult nutrition.
Core Diagnostics Sales Growth: Core Laboratory Diagnostics sales grew by 4.5%, excluding COVID testing, supported by global demand for routine diagnostic testing and large account wins.
MedTech Sales Surge: MedTech sales grew over 13%, with continuous glucose monitors exceeding $1.6 billion in sales, reflecting a 21% growth in the quarter.
Structural Heart Sales Growth: Structural heart sales grew more than 16%, driven by strong performance across surgical valves and transcatheter repair products, with market share gains in TAVR.
Negative
Nutrition Segment Sales Growth: Sales in the Nutrition segment increased only 3.5%, with international pediatric nutrition experiencing softness due to poor commercial execution, leading to share losses.
Core Lab Sales Growth: Core Laboratory Diagnostics sales growth was only 4.5%, negatively impacted by the implementation of the Value-Based Purchasing (VBP) program in China, which is expected to continue affecting growth.
Gross Margin Decline: Adjusted gross margin ratio decreased to 56.3% of sales, indicating potential challenges in cost management despite overall sales growth.
Currency Fluctuation Impact: The unfavorable foreign exchange impact of 2.5% on third-quarter sales highlights vulnerability to currency fluctuations, which could affect future revenue projections.
Tax Rate Impact on Earnings: The adjusted tax rate of 15% reflects a higher tax burden, which could limit net earnings growth moving forward.
ABT FAQs
How does ABT typically perform around its earnings report dates?
Is Earnings call transcript: Abbott Labs Q3 2024 sees steady growth positive or negative?
How can historical earnings data help predict future stock performance?
ABT Earning Call Sentiment
Earnings call transcript: Abbott Labs Q3 2024 sees steady growth
ABT.N
0.18%Positive
The earnings call highlights strong financial performance with an 8% organic sales growth and a 13% increase in MedTech sales. The company maintains its full-year revenue guidance and announces a $7 billion share repurchase program, indicating confidence in future growth. Despite some challenges in international markets, management's optimistic guidance and strategic investments in high-growth areas suggest a positive outlook. The Q&A section reinforces confidence in market opportunities, particularly in the CGM and structural heart markets, further supporting a positive sentiment.
